Condition: Acute Leukemia · Lymphoblastic Leukemia · Lymphoblastic Lymphoma · Sponsor: University of Chicago
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.
This description comes directly from the study's public registry record.
Caner Saygin, MD · 773-834-8982 · caner.saygin@bsd.uchicago.edu
Wendy Stock, MD · 773-834-8982 · wstock@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| University of Chicago Medicine Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| University of Rochester Medical Center, Wilmot Cancer Center | Rochester, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06207123